QTEX

Executive Summary

A medtech's second life as a quantum-interconnect option

QTEX is not a quantum computer company — it is a pivot story. Formerly Inspira Technologies (IINN), an Israeli developer of the ART100 respiratory life-support system, it rebranded as QTREX Quantum on May 20, 2026 and redirected its Additively Manufactured Electronics (AME) platform at printed monolithic interconnects inside dilution cryostats — a real hardware bottleneck for scaling quantum machines. The tape shows why the story matters: disclosure of active testing with an unnamed top-five global quantum computing company drove the stock from ~$0.30 to a $3.41 intraday high in late May, and it has since round-tripped −75.6% from the $3.85 52-week high to $0.9399. Genuine progress since: two U.S. DoD laboratories operating AME systems, with a joint development program targeted for formalization in Q4 2026, a Northeastern University research collaboration, and a $10M private placement. But QTEX remains pre-revenue in quantum with a going-concern opinion, and dilution and pivot-credibility risk dominate until a first named commercial contract lands.

Market Snapshot

A $34M option on printed cryogenic interconnects — Post-spike consolidation: price sits 75.6% below the May peak, pinned between the 200-DMA floor and the 50-DMA overhead, with no revenue base underneath

Price (2026-08-17)

$0.9399

NasdaqCM; warrants trade as QTEXW

Market cap

$34M

On 35,949,247 issued shares (EDGAR, 2025-12-31); the Jul 2026 F-1 shows 55.7M shares — ~$52M effective

52-week range

$0.283–$3.85

Low pre-pivot as Inspira; high set in the late-May quantum spike

vs 52-week high

−75.6%

Full round-trip of the rebrand rally

50-DMA

$1.37

Price ~31% below — near-term downtrend intact

200-DMA

$0.95

Price sitting right on the long-term line

RSI (14)

40.7

Neutral-weak; not yet oversold

Quantum revenue

No quarterly revenue/EPS in EDGAR (FPI, 6-K filer); pre-revenue pivot

Growth Story

From respirators to cryostats: the AME interconnect pivot

Top-5

Quantum partner in active testing

Unnamed top-five global quantum company testing QTREX AME interconnects inside its cryogenic refrigerator architecture (May 2026 disclosure)

2 labs

U.S. DoD laboratories running AME systems

Second Pentagon lab confirmed Aug 2026; Q4 2026 target to formalize a joint quantum development program

$10M

Private placement (May–Jun 2026)

6,666,667 shares to an institutional investor (~$1.50/sh) funding the quantum build-out; legacy ART100 medtech monetized alongside

MAY 20, 2026

Rebrand: Inspira → QTREX Quantum (QTEX)

Shareholder-approved name change; Nasdaq ticker flips IINN → QTEX. Strategic focus shifts from respiratory medtech to AME and quantum connectivity infrastructure.

MAY 22–29, 2026

~10x spike on top-five partner disclosure

News of collaboration talks and active AME-interconnect testing with an unnamed top-five quantum computing company sends shares from ~$0.30 to a $3.41 intraday high; ~322% weekly gain, cap briefly ~$130M.

JUN 2026

$10M private placement; Nasdaq compliance regained

6,666,667 ordinary shares to a new institutional investor for ~$10M gross; on June 11 the company regains the $1.00 minimum-bid and MVLS requirements after 11 straight days ≥ $1.00.

JUL 2026

First DoD lab + Northeastern University

July 6: a U.S. government laboratory begins operating QTREX's AME system. July 27: research collaboration with Northeastern on cryogenic quantum interconnect micro-structures, with first-option commercial licensing rights to QTREX. F-1 (effective Jul 31) registers 6.79M Armistice warrant shares.

AUG 2026 →

Second Pentagon lab; Q4 program target

A second, distinct DoD laboratory is actively running QTREX's printed cryogenic interconnects; parties target Q4 2026 to formalize a joint quantum development program. Stock consolidates near $0.94, back below the Nasdaq $1.00 line.

Earnings & Signals

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

FY+1 EPS Consensus≈ −$0.03 next half-year per TradingView (single-source, low reliability); TTM EPS −$0.446 (Investing.com)

FY+2 EPS ConsensusN/A — no credible FY2027 estimates exist

PEG RatioN/A — loss-making, pre-revenue in its new quantum business

Forward P/EN/A — negative forward earnings

EPS Revisions (90d)↑0 ↓0 (No tracked estimate revisions — coverage too thin for a revisions signal)

Guidance AccuracyN/A — company issues milestone-based press releases, not financial guidance; no revenue guidance on record since the QTREX pivot

Earnings Surprise Track Record

H2 2025 (semi-annual FPI reporter) Est: −$0.20 Act: −$0.21 −5.0%

Earlier periods Est: N/A Act: N/A —

Beat Rate0/1 on the only tracked period (TradingView); sample too small to be meaningful

Insider Activity (90 Days)

Net Buying/Selling≈ −$0.4M (net selling; announced buy program not yet executed)

Sell/Buy RatioAll sells, no open-market buys reported yet

Mixed-to-cautious: roughly $0.4M of insider sales in the past three months (Simply Wall St data), including net sales of 90,000 shares by Yafit Tehila and 50,000 by Daniella Yechezkely Hayon — set against a June 22, 2026 announcement that the CEO, chairman and senior management intend to buy up to 2M shares over 12 months, but only after H1-2026 results are out. Watch whether announced buying actually prints.

CEO Dagi Ben-Noon and chairman Tal Parnas jointly committed to the up-to-2M-share personal purchase plan (Jun 22, 2026); announced on the heels of the insider-selling trend, which reads partly as a confidence signal to a falling tape.

Peer Comparison

Relative Valuation vs. Competitors

Company	P/E (fwd)	EV/Rev	Rev Growth	Gross Margin
QTREX Quantum	n/m	n/m — pre-revenue	n/m	n/m
IonQ	n/m (loss-making)	~109× (P/S)	+287% YoY (Q2 26, $80.1M)	n/a
Rigetti Computing	n/m (loss-making)	~836× (P/S)	+185% YoY (Q2 26, $5.1M)	n/a
D-Wave Quantum	n/m (loss-making)	~791× (P/S)	~flat YoY (Q2 26, $3.1M)	n/a
Arqit Quantum	n/m (loss-making)	~352× (P/S)	n/a	n/a

QTEX cannot be valued on multiples: EDGAR shows no quarterly revenue or diluted EPS, so every ratio is honestly n/m. The peer set is itself extreme — IonQ, Rigetti, D-Wave and Arqit all trade at triple-digit price-to-sales — meaning the sector prices narrative, not earnings. QTEX is also not a direct competitor: it sells picks-and-shovels interconnect hardware INTO cryostat builders rather than competing qubit modalities. At a $34M headline cap (~$52M on the post-placement share count) it is priced as a small option on AME adoption; a single named commercial contract would be the re-rating event, and its absence is the bear case.

Valuation

Price Targets & Scenarios

Scenario	Price Target	Assumptions	Probability
DoD Program Signs + Named Commercial Contract	$2.50	The Q4 2026 DoD joint development program is formalized into a funded agreement, the top-five quantum partner converts testing into a named commercial supply contract, and first quantum revenue prints. The stock re-rates toward the May spike zone on sector narrative multiples; dilution continues but at higher prices.	15%
Milestone Drip, Dilution Grind	$0.75	More announcement-grade progress (lab deployments, university IP, grant milestones) but no signed commercial contract. The ~6-month stated runway forces another raise near or below market; the $0.70 Armistice warrant strike acts as a price magnet and the Nasdaq $1.00 deficiency clock restarts, keeping a reverse split on the table.	40%
Going-Concern Bites, Reverse Split	$0.35	Financing terms deteriorate, the DoD program slips or stays unfunded, and the going-concern language persists into the next annual report. A dilutive raise plus a reverse split to hold listing compresses the equity back toward pre-pivot levels on a split-adjusted basis.	45%

Probability-Weighted Target: $0.83 (~12% downside vs $0.94 — bear/base dominate; the DoD-contract bull tail is real but unsigned and unfunded)

$0.83

Weighted

Bull $2.5015%

Base $0.7540%

Bear $0.3545%

Analyst Consensus

Litchfield Hills Research

$2.00

Buy — initiated Jun 2025 on predecessor Inspira Technologies (IINN), pre-dating the May 2026 quantum pivot; last rating on record per Benzinga

Aggregator consensus (unnamed)

$5.00

Stockopedia/TradingView show a single $5.00 target (min = max) — a lone, likely stale estimate carried over from the Inspira era, not fresh QTEX coverage

No coverage found

—

No major-firm coverage identified since the May 2026 rebrand to QTREX Quantum

No coverage found

—

No bulge-bracket or mid-tier bank coverage identified; WallStreetZen lists the 1-year price target as N/A

1 Buy · 0 Hold · 0 Sell — Effectively uncovered: the only named rating is Litchfield Hills' Buy/$2.00 from June 2025, initiated on the company's prior identity (Inspira Technologies, a medical-device firm) before the April–May 2026 pivot into quantum interconnects. Aggregator targets ($2–$5) are single-analyst and stale, so no meaningful consensus exists for QTEX as a quantum company.

Technical

Key Levels & Options Intelligence

S/RSupport & Resistance

52-week high (May–Jun 2026 rebrand spike)

$3.85

50-DMA — declining, first real overhead

$1.37

Nasdaq $1.00 bid line / Jun–Jul range floor

$1.00–1.10

200-DMA — being tested now

$0.95

Last price (Aug 17, 2026)

$0.94

Armistice warrant strike — dilution magnet / soft support

$0.70

52-week low (pre-rebrand, as Inspira)

$0.283

OptOptions & Sentiment

Listed options: None found — OptionCharts returns 'no options data for ticker QTEX'; no active chain surfaced
Put/call ratio: n/a — no listed options chain to measure
Implied volatility: n/a — no options; realized-risk proxy is a 4.28 beta (stockanalysis.com)
Short interest: ~3.3M shares, ~6.8% of float (Finviz-tracked data)
Days to cover: ~1.0 day — shorts can exit quickly; low squeeze fuel
Short-interest trend: Down ~60% over 12 months — bears largely covered after the collapse from $3.85
Momentum read: RSI(14) 40.7 — neutral-weak; price below the declining $1.37 50-DMA
Net sentiment: Bearish drift, not panic: no derivatives market exists, so sentiment must be read from the tape — lower highs since June, sitting on the 200-DMA

Conviction Analysis

Systematic Conviction Score: 17/100 (Low)

Analyst Alignment

30%

FCF Visibility

25%

Catalyst Clarity

20%

Valuation Safety

15%

Mgmt Quality

10%

No real sell-side coverage exists since the quantum rebrand — zero analyst validation either way (8). Cash flow is entirely financing-dependent: ~$289K ttm revenue vs a −$13.2M net loss, a going-concern opinion and a stated ~6-month runway (5). Catalysts are identifiable and dated — H1-2026 results, the insider buy window, the Q4 2026 DoD program target — but all are announcement-grade, not revenue-grade (40). Valuation offers no floor: warrants struck at $0.70 and ~$12.6M of shelf capacity supply stock below the market price (15). Management gets credit for raising $10M and regaining Nasdaq compliance, debited for recent insider selling and a rebrand-driven narrative from the same team whose device business never commercialized (30). Weighted score 17 — Low conviction, consistent with a SELL despite a genuine DoD-driven bull tail.

Risk & Ownership

Risk Assessment & Insider Signals

OOwnership & Insider Signals

Armistice Capital Master Fund — ~10.8% stake via warrants: Per the July 2026 F-1, Armistice Capital (Steven Boyd) is the selling shareholder behind 6,785,715 registered warrant shares at a $0.70 strike, subject to a 4.99% beneficial-ownership blocker — a financing holder, not a long-term strategic owner.
Unnamed 'fundamental institutional investor' — $10M placement: In late May 2026 a new institutional investor bought 6,666,667 ordinary shares in a $10M private placement (announced alongside the QTEX rebrand), capped by a 9.99% beneficial-ownership limitation. The buyer has not been publicly named.
CEO Dagi Ben-Noon — ~3.77% direct ownership: Simply Wall St data shows CEO Dagi Ben-Noon, in the seat since 2017 at predecessor Inspira, directly owning ~3.77% of shares (~$2.2M at recent prices). Chairman is Tal Parnas.
Announced management buy program — up to 2M shares: On June 22, 2026 QTREX announced the CEO, chairman and senior managers plan to buy up to 2 million ordinary shares with personal funds over 12 months, with purchases beginning only after the June 30, 2026 period results are released.
Thin institutional base; retail-dominated float: Beyond the placement investor and Armistice, no meaningful 13F institutional roster or analyst coverage surfaced — consistent with a $34–52M-cap foreign private issuer. Short interest ~3.3M shares (~6.8% of float, ~1.0 days to cover).
Share count in motion — 35.9M → 55.7M in seven months: Outstanding shares grew ~55% from Dec 31, 2025 to Jul 19, 2026, with a path to 62.5M on full warrant exercise — ownership percentages for all holders are a moving target.

Risk Heatmap

Quantified Risk Assessment

Severity Risk Factor Prob. PT Impact

High Going concern — ~6-month stated cash runway

The 2025 audited financials carry an explanatory paragraph raising substantial doubt about QTREX's ability to continue as a going concern. The July 2026 F-1 states existing cash funds operations for only about the next six months (cash ~$3.16M at Dec 31, 2025, before the May 2026 $10M placement), and that substantial additional capital will be needed on terms that may not be favorable.

60% -40%

High Serial dilution — shares up ~55% in seven months, more registered

Shares outstanding rose from 35,949,247 (Dec 31, 2025) to 55,708,771 (Jul 19, 2026 per the F-1) after the $10M placement. Two shelf registrations totaling ~$12.6M are on file, and the F-1 registers 6,785,715 warrant shares for resale — full exercise takes the count to 62,494,486.

80% -25%

High Nasdaq minimum-bid relapse and reverse-split risk

Deficient under Rule 5550(a)(2) from March 2025; only regained the $1.00 bid and MVLS requirements on June 11, 2026. At $0.94 the stock is back below the line; a renewed 30-day breach restarts the deficiency clock, and management has flagged a reverse share split as the fallback tool.

50% -30%

High Unproven pivot: medical-device company rebranded as quantum play

QTREX is the former Inspira Technologies (IINN), an Israeli respiratory-device maker still SIC-classified under surgical/medical instruments, that took the QTEX ticker on May 20, 2026. Trailing revenue is ~$289K with a −$13.2M net loss; the quantum thesis rests on press releases and a $1M Israel Innovation Authority grant, not commercial contracts.

55% -35%

Medium Armistice warrant overhang repriced to $0.70

The F-1 registers 6,785,715 resale shares for Armistice Capital Master Fund, with warrants repriced from $1.28 down to $0.70 and extended to Feb 2031. A large repriced strike ~25% below the current price creates a standing supply source and caps rallies; Armistice is a repeat micro-cap financier known for rapid monetization.

70% -15%

Medium Extreme volatility, momentum-driven tape

Beta of 4.28, a 52-week range of $0.283–$3.85, a +322% pop on the rebrand news and a −75.6% drawdown from the high mark this as a sentiment-driven micro-cap where technicals move faster than fundamentals — gap risk is severe in both directions.

75% -20%

Recommendation

Summary

Rating

SELL

Conviction

Low

Price Target

$0.83

Timeframe

12 months

Upside

-12%

Position Size

0% — avoid; speculative accounts ≤0.5% max

Entry Strategy

Tranche 1 — 0%

Avoid

We do not recommend initiating a long position. Going-concern language, a ~6-month stated runway, $0.70 warrant supply and reverse-split risk dominate any milestone news flow. For accounts that must hold, treat as a sub-0.5% lottery ticket only.

Tranche 2 — spec only

<$0.70

Only consider a tiny speculative starter below the Armistice warrant strike AND after the Q4 2026 DoD joint development program is actually signed and funded — an announcement of intent does not qualify.

Tranche 3 — re-underwrite

Post contract

Re-underwrite from scratch only when a named commercial customer signs a revenue-bearing interconnect contract and the next filing shows ≥12 months of cash — do not average down into dilution or a reverse split.

1-Year Price & Key Levels